Come and join us across the globe
Sign In

NEWS

PRESS RELEASE

New study shows use of EMBOTRAP® device clot retriever during treatment...

ARISE II Clinical Trial Results Published in Stroke Journal  Gothenburg, Sweden – May 16, 2018 –EMBOTRAP® Device, a device designed to remove clots from the brain following an ischemic stroke, demonstrated high success rates in restoring blood flow and patients achieved high rates of functional independence, according to ARISE II (Analysis of Revascularization in Ischemic Stroke with EMBOTRAP® Device), a new clinical trial published in Stroke [Journal]. 

PRESS RELEASE

CERENOVUS receives FDA clearance for next generation stent retriever dev...

EMBOTRAP II Revascularization Device Captures and Removes Life-threatening Blood Clots, Rapidly Restores Blood Flow IRVINE, California, May 21, 2018 - CERENOVUS, part of the Johnson & Johnson Medical Devices Companies, announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EMBOTRAP II Revascularization Device, a next generation stent retriever used to capture and remove life-threatening blood clots from the brain following an ischemic stroke.

PRESS RELEASE

Viz.ai to present expanded data on ALADIN and new data on ADVANCE expand...

Breadth of ALADIN data to reinforce results in expanded scans across multiple centers Important research will highlight a potential use case for Viz.ai’s deep learning, artificial intelligence algorithms beyond acute ischemic stroke.

BREAKING NEWS

BREAKING NEWS

PRESS RELEASE

Stryker’s Trevo™ Retriever becomes first and only device indicated for a...

Kalamazoo, Michigan, USA – Following the expanded indication in the United States by the Food and Drug Administration (FDA) in February, Stryker’s Trevo Retriever has received CE marking as a front-line treatment for patients experiencing acute ischemic stroke up to 24 hours from symptom onset, increasing the treatment window by 18 hours.

BREAKING NEWS

Come and join us across the globe